Real-World Outcomes From Third-Line SCLC Treatment Show Need for More Options

Patients with extensive-stage small cell lung cancer (ES-SCLC) see little benefit from third-line (3L) therapies, according to a new analysis of real-world outcomes.¹ The authors of the analysis say it underscores the “urgent” need for novel…